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Copyright © 200? JCBN Summary Low caloric diet (LCD) is used for weight loss. Paraoxonase 1 (PON-1) is associated
with the antioxidant functions of high-density lipoprotein (HDL). Among limited data on the
relationships between obesity and PON-1, there has been no study on the effects of a stand-
alone LCD on the physiological lactonase activity of PON-1. We investigated the prospective
effects of LCD intervention (2 months) for weight loss on serum PON-1 activities (lactonase,
arylesterase [mono-esterase] and tri-esterase) and HDL cholesterol (HDL-C), and their
association with low-density lipoprotein cholesterol (LDL-C) in overweight and non-morbidly
obese but otherwise healthy women (n = 30; mean age, 50.3 years; mean body mass index
[BMI], 28.5 kg/m2). In addition to the data such as BMI, blood pressure, blood glucose and
lipids, PON-1 activities were examined between pre- and post-intervention. The intervention
reduced all metabolic outcomes, and PON-1 lactonase activity (determined with 5-
[thiobutyl]butyrolactone) significantly decreased by 6.1%, paralleled by arylesterase (by
7.3%) and tri-esterase (by 7.8%). In multiple regression analysis, the percent change of
PON-1 lactonase was significantly, positively and independently correlated to that of LDL-C
(β = 0.51), HDL-C (β = 0.40), and BMI (β = 0.37). Our results showed that the solo diet
treatment on weight loss might reduce serum PON-1 lactonase activity with reduced HDL-C
and LDL-C. The relationship between the lactonase and LDL-C may be adaptive, plausibly
hypothesizing less need for PON-1 activity as an antioxidant property to protect lipoproteins.
Further research is needed to confirm this prediction.
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Introduction
Obesity is a crucial risk factor in the development of its
co-morbid diseases such as metabolic syndrome and
atherosclerotic disorder including cardiovascular disease
(CVD), and the increased prevalence of obesity is a major
problem in many countries [1]. Impaired high-density
lipoprotein (HDL) antioxidant defenses in obese people,
such as a decreased activity of the HDL-associated enzyme,
paraoxonase 1 (PON-1), have recently received increased
attention [2]. PON-1, an esterase carried by HDL, is known
to exert a protective effect against oxidative damage of
cells and lipoproteins, playing an anti-inflammatory and
anti-atherogenic role [2–4]. In fact, a low circulating PON-1
activity has been reportedly associated with obesity,
metabolic syndrome and CVD [2, 5–7].
Low caloric diet (LCD) is one of the treatment modalities
adopted as a part of lifestyle management on weight loss,
leading to the improvement of metabolic and cardiovascular
conditions [8, 9]. A few studies have addressed the changes
in circulating PON-1 activity in the treatment intervention
for obesity [10–12]. These previous results are not always
consistent. In one, weight loss by gastric banding signifi-
cantly increased PON-1 activity in morbidly obese patients
[10]. In another study with obese patients treated with
orlistat (an anti-obesity drug), PON-1 activity was signifi-
cantly increased [11]. Weight reduction via a combination of
exercise and diet energy restriction significantly reduced
PON-1 [12]. As mentioned above, HDL is widely recognized
to be an anti-atherogenic lipoprotein. Whereas the influence
of calorie restriction diet for weight loss on lipid profiles,
circulating HDL cholesterol (HDL-C) in particular, is
reportedly controversial, HDL-C has been known to be often
reduced in short-term diets [13–17]. The clinical signifi-
cance and detailed mechanism of this is presently unclear,
so accumulating data are required. Turnover studies have
documented the changes in clearance of HDL-C during
dietary modification [18], and the reduction in chylomicron-
derived HDL formation following caloric (lipid) restriction
diet is discussed as an alternate explanation [14]. There is an
opinion that the diet-induced HDL-C drop does not increase
CVD risk [19]; however, whether this diet-induced reduc-
tion of HDL-C is beneficial/harmful remains debatable.
One of the physiological roles of HDL involves the action
of PON-1 [2, 4], and to evaluate a functional aspect of HDL
in measuring PON-1 activity may yield further insights on
this issue. The presence of dysfunctional HDL may, at the
same HDL-C levels, signify quite different outcomes, and
the same may be said about inflammatory/anti-inflammatory
HDL. PON-1 hydrolyzes lipid peroxides, imparting protec-
tion to low-density lipoprotein (LDL) against oxidation [4,
6]. Although conflicting results exist [20], a low PON-1
activity generally implies their reduced ability to protect
LDL from oxidation, resulting in increased oxidized LDL
[6]. There is a positive association between oxidized LDL
and LDL cholesterol (LDL-C) concentrations [20], and a
LCD treatment may have the beneficial effects of reducing
LDL-C levels. Therefore, when we assess the effects of LCD
on PON-1, its association with the beneficial changes of
LDL-C is an important factor to consider, that is one aim of
the present study.
Moreover, the previous studies to observe the association
between weight loss and PON-1 had two main limitations.
First, none has addressed the effects of LCD as a stand-alone
treatment on PON-1 activity. Interventions by a combination
of exercise and diet, or diet and orlistat, could make it
difficult to determine which aspect of the intervention is
responsible for the change of PON-1 (or HDL-C) and to
what extent. In particular, when a diet treatment is combined
with exercise, HDL-C metabolism can be modified [21, 22]
by the improvement of skeletal muscle/liver and insulin
homeostasis through exercise [23,  24]. One of our study
aims was thus to investigate the effects on PON-1 of an
intervention by stand-alone ‘LCD’ to generate results that
are easier to interpret and accordingly more meaningful in
practice. The second limitation of the previous studies is
that they have employed substrates that can not necessarily
reflect the physiological activity of PON-1, which is recently
regarded primarily as a lactonase [25, 26]. Hence, measuring
the lactonase would provide news in research on the diet-
PON-1 association.
With this background in mind, the present study investi-
gated, in a population of overweight and not-morbidly obese
but otherwise healthy subjects, the prospective effects of a
solo LCD intervention for weight loss on the physiological
lactonase activity of serum PON-1. We also addressed its
association with changes in LDL-C, HDL-C and other
clinical outcomes. Taking into account the gender difference
in HDL-C metabolism as a powerful confounder [16, 27],
our work was restricted only to a female cohort.
Subjects and Methods
In total, 30 healthy and free-living Japanese women, aged
33 to 63 (mean age, 50.3 ± 8.5) years, with an overweight/
obesity level of body mass index (BMI) (mean, 28.5 ± 3.3
kg/m2; range, 24.3 to 38.6) participated in this study. Exclu-
sion criteria were as follows: the use of medications and
nutrient supplements, pregnancy, current smoking, alcohol
abuse, psychological contraindications as determined by
study investigators, or known hypersensitivity to any of the
ingredients of the formula. The study was approved by the
Ethics committee of Kyoto Medical Center, and all subjects
gave informed consent.
Concerning the LCD prescription, during the study inter-
vention period, subjects were placed on the LCD (5023 kJ/Diet for Weight Loss and PON-1
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day) (consisting of protein, 47%; lipid, 7%; carbohydrate,
40%) with meal replacement (Diet’sTM, Suntory Co. Ltd.,
Osaka, Japan) every dinner for 2 months. The subjects were
also instructed by trained dieticians about the planning of
nutritionally balanced diets, and the adherence was checked
through dietary daily records. They were encouraged not to
change usual physical activity during the intervention.
The subjects’ data at baseline (pre-intervention) and the
end of 2 months’ study (post-intervention) were used. In an
overnight fast, we confirmed the subjects’ data on BMI,
blood pressure (measured using a mercury sphygmomano-
meter), plasma glucose (enzymatic kinetic method, Shino-test
Co. Ltd., Tokyo, Japan) and lipids such as total cholesterol
(enzymatic kinetic method, Wako Pure Chemical Industries
Co. Ltd., Tokyo, Japan) and triglyceride (enzymatic kinetic
method, Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan).
Both HDL-C and LDL-C were measured using a homoge-
neous assay (Daiichi Pure Chemicals Co. Ltd.).
Serum PON-1 lactonase activity was kinetically deter-
mined at 37°C using 5-(thiobutyl)butyrolactone (TBBL), a
lactone substrate that is analogous to γ-nonanoic lactone,
yet releases upon hydrolysis of the γ-butyrolactone ring, and
recorded at 405 nm in a VERSA max (Tunable) Microplate
Reader [25,  26]. Serum PON-1 tri-esterase activity was
determined using paraoxon as a substrate, from the initial
velocity of p-nitrophenol production at 37°C, and recorded
at 405 nm [28]. Serum PON-1 arylesterase (mono-esterase)
activity was determined using phenylacetate as a substrate
and kinetically measured at 37°C by recording absorbance
changes at 270 nm [28, 29].
Data are expressed as mean ± standard deviation (SD).
The level change between pre- and post-intervention in
respective variables was tested by paired t test. To detect
the correlations between the percent change of PON-1,
HDL-C and LDL-C, we used Pearson’s rank coefficient test
as well as multiple regression analysis controlling for the
above variables and age. A p<0.05 was considered signifi-
cant.
Results
All subjects completed the present LCD intervention. The
data on respective variables in pre- and post-intervention
were listed in Table 1. During the intervention, most vari-
ables (except for systolic blood pressure which did not
achieve a statistical significance level) were significantly
reduced. Notably, PON-1 lactonase, as well as arylesterase
and tri-esterase activities, were significantly reduced.
As listed in Table 2, in the simple correlation tests, the
percent change of BMI or LDL-C was significantly and
positively correlated to that of PON-1 lactonase activity,
along with age. Multiple regression analysis on PON-1
lactonase activity, adjusted for age, BMI, LDL-C and HDL-
C, revealed that the percent change of LDL-C, HDL-C,
and BMI (the correlation degree ranked in this order) was
significantly, positively, and independently correlated to
that of lactonase activity. Furthermore, multiple regression
analysis on the percent change of HDL-C, adjusted with age,
BMI, LDL-C and PON-1, revealed that the percent change
of BMI was significantly, inversely, and independently
correlated, and PON-1 lactonase activity was significantly,
positively, and independently correlated to HDL-C. Addi-
tionally, the results in the correlation tests on arylesterase
or tri-esterase activity were similar with those in PON-1
lactonase activity (data not shown).
Table 1. Outcome variables before and after a low calorie diet intervention
Data are mean ± SD. HDL: high-density lipoprotein, LDL: low-density lipoprotein, PON-1: paraoxonase 1. a PON-1 tri-esterase:
activity measured with paraoxon, b PON-1 arylesterase (mono-esterase): activity measured with phenylacetate, c PON-1 lactonase:
activity measured with 5-(thiobutyl)butyrolactone (TBBL). PON-1 tri-esterase activity decreased by 7.8%, arylesterase by 7.3% and
lactonase activity by 6.1%, respectively. Significance level (paired t test between pre- and post-intervention): *p<0.05, **p<0.01.
Variables Pre-intervention Post-intervention p value
Body mass index (kg/m2) 28.5 ± 3.3 26.2 ± 3.3 <0.001**
Systolic blood pressure (mmHg) 128.7 ± 15.6 125.0 ± 15.7 0.062
Diastolic blood pressure (mmHg) 80.0 ± 10.9 75.1 ± 9.9 0.001**
Glucose (mmol/L) 5.1 ± 0.6 4.8 ± 0.5 <0.001**
Total cholesterol (mmol/L) 5.77 ± 0.93 5.38 ± 0.96 <0.001**
Triglyceride (mmol/L) 1.12 ± 0.74 1.00 ± 0.65 0.030*
HDL cholesterol (mmol/L) 1.64 ± 0.37 1.56 ± 0.31 0.049*
LDL cholesterol (mmol/L) 3.27 ± 0.67 2.99 ± 0.70 <0.001**
PON-1 tri-esterase (U/L)a 153.6 ± 60.6 141.2 ± 53.4 0.002**
PON-1 arylesterase (U/L)b 123.2 ± 21.2 114.3 ± 22.2 0.001**
PON-1 lactonase (U/L)c 147.2 ± 20.2 138.2 ± 17.3 <0.001**K. Kotani et al.
J. Clin. Biochem. Nutr.
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Discussion
Our study displays the effects of short-term LCD inter-
vention for weight loss on PON-1 physiological lactonase
activity and HDL-C, and their association to LDL-C changes,
in healthy overweight/obese women. So far, evidence on the
influence of weight loss on PON-1 has been inconsistent
[10–12], and this may be partly explained by the differences
in intervention methods and populations. In our cohort, all
measured variables including BMI, HDL-C and PON-1
were reduced, and the reduction of BMI showed a signifi-
cant positive correlation to that of PON-1. A previous study
has reported that a combination of exercise and diet could
reduce PON-1 in subjects with the metabolic syndrome [12],
though in this case, the element of exercise may make some
differences in the HDL metabolism from a solo diet treat-
ment [23, 24]. Another previous study has also implicated
that a healthy diet, for instance focused on vegetables, might
reduce PON-1, though this study was not necessarily for
obese subjects [30]. Taken together, our results seem to raise
the possibility that a diet treatment reduces PON-1. Whether
the mechanism was due to metabolic changes of HDL-C
[14,  18] or a reaction to diet- and weight loss-induced
reduction of oxidation (as described later) remains to be
determined presently, but at least, our study adds to the
present knowledge in two main areas: 1) the results from a
better defined cohort of a homogeneous population of
healthy and overweight/obese (non-morbidly) individuals
and a well-controlled intervention by diet alone, 2) the
novelty of demonstrating a decrease in lactonase activity
that parallels the mono-esterase and tri-esterase changes.
PON-1 catalyzes the hydrolysis of numerous substrates:
lactones, thiolactones, esters and phospho-triesters, including
paraoxon, from which its name is derived. Nevertheless,
only after many years of research, it has became apparent
that PON-1 is actually a lactonase, catalyzing the hydrolysis
and synthesis of several lactones [25, 26, 31]. The other
activities, such as arylesterase and phospho-triesterase,
might be simply promiscuous, although they are used in
clinical laboratory research as a practical way of measuring
PON-1 activities (seen in the previous articles on weight
loss) and even the commercial kits have appeared on the
market this year. The physiological substrates of PON-1
remain uncertain; however, they are presumably lactones in
food components or derivatives of fatty acid oxidation chain
reactions such as 5-hydroxyeicosatetraenoic acid lactone.
These end-product lactones of fatty acid oxidation may be
found in LDL, HDL or macrophages [25, 26].
Based on the current wisdom that PON-1 is a protective
factor against CVD [5–7], the lowering of such PON-1
activities might be interpreted as a detrimental effect of the
diet. However, we think that this has to be balanced by the
beneficial effects produced by the diet on other well-known
risk factors for CVD. In this regard, our study has found an
association that may explain this apparent ‘paradoxical’
effect of the LCD intervention. Indeed, to the best of our
knowledge, this is the first description that there is a
significant relationship between the lowering of PON-1
activity (its lactonase or the others) and that of LDL-C.
Namely, the correlation between PON-1 and LDL-C
changes in the LCD intervention has not been previously
reported, although whether this is a specific effect of LCD is
unclear. Interestingly, from our study results, this relation-
ship was not fully explained by the reduction in HDL-C.
Shedding more light on the mechanism for the relationship
between PON-1 and LDL-C is a future challenge, but we
would suggest this hypothetical flow of events. PON-1
hydrolyzes lipid hydroperoxides and lactones in oxidized
Table 2. Correlations between the percent changes of HDL cholesterol, LDL cholesterol, and
PON-1 lactonase activity during the intervention period
HDL: high-density lipoprotein, LDL: low-density lipoprotein, PON-1: paraoxonase 1. r: Pearson’s
rank correlation coefficient, β: multiple regression coefficient (adjusted for all listed variables).
Significance level: *p<0.05, **p<0.01.
Variables r (p value) β (p value)
ForPON-1 lactonase activity
Age (years) 0.463 (0.010*) 0.021 (0.906)
Body mass index (kg/m2) 0.408 (0.025*) 0.366 (0.041*)
LDL cholesterol (mmol/L) 0.604 (<0.0001**) 0.509 (0.001**)
HDL cholesterol (mmol/L) 0.278 (0.137) 0.399 (0.017*)
ForHDL cholesterol
Age (years) 0.276 (0.140) 0.419 (0.028*)
Body mass index (kg/m2) –0.286 (0.125) –0.606 (0.002**)
LDL cholesterol (mmol/L) –0.044 (0.819) –0.316 (0.103)
PON-1 lactonase activity (U/L) 0.278 (0.137) 0.522 (0.017*)Diet for Weight Loss and PON-1
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lipoproteins, imparting protection to LDL against oxidation
[4, 6, 25, 26, 28, 29]. LDL oxidation could be related to
LDL-C levels [25] and/or to obesity [32, 33]. Weight loss
and caloric restriction diet induces the prominent reduction
of the LDL oxidation [32, 34]. Our study demonstrated a
weak correlation between the decrease levels of BMI and
those of LDL-C (r =0 . 2 8 8 ,  p>0.05 [data not shown in the
result section]), as well as an independently significant
correlation of the decrease levels of PON-1 to those of BMI
or LDL-C (shown in Table 2). Such a weak correlation
between obesity and LDL-C (a quantity measure of LDL),
relative to the measures of LDL oxidation (a concept of
quality of LDL), has been noted previously [32, 33]. Thus,
our results on the relationship between PON-1 and LDL-C
might be explained, a priori, as a consequence of less need
for LDL protection by the LDL-C concentration decrease
and weight loss following a LCD intervention. Importantly,
in the last years, the re-evaluation of HDL physiology
stresses its pro- or anti-inflammatory functions according
to different circumstances and its pleiotropic functional
activities [35, 36]. Hence, the decrease in PON-1 as well
as HDL-C in response to LCD may not be detrimental but
a physiologically appropriate or adaptive phenomenon.
Whether this is due to adjustments in the expression of
PON-1 or to re-distribution of HDL particles needs to be
addressed in further studies.
As a study limitation, we examined a restricted number of
women only. More studies on a larger scale of subjects,
including men, and other ethnic populations (may have
different genetic factors) are needed to establish our results
[7, 13]. Also, studies evaluating PON-1 mass changes are
warranted. Even though we did not measure actual PON-1
mass, the fact that all three PON-1 activities measured are
reduced in a similar manner suggests that the changes are
likely due to changes in PON-1 concentrations. Since the
correlation with changes in HDL-C is not so strong, this may
indicate lower amounts of PON-1 per unit HDL particle.
Conclusions
In a cohort of healthy overweight/obese women, we
showed for the first time a reduced PON-1 lactonase activity
(as well as its mono- and tri-esterase activities) during a
LCD intervention on weight loss, with a significant correla-
tion with the reduction of LDL-C. The present results on
the relationship between PON-1 and LDL-C may be
pointing to the PON-1 activity level needed to protect
LDL from oxidation, as an adaptive response to the LDL-C
decrease and weight loss by the diet treatment. Moreover,
the apparently paradoxical changes in HDL-C and PON-1
lactonase activity seen in the diet on weight loss would
emphasize the need for the clinical laboratory to explore
lipoprotein metabolisms beyond the simple static HDL-C
measurement. Further research is needed to confirm our
theory.
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